January 7, 2017: According to 13F filings, institutional traders are accumulating Eleven Biotherapeutics. Firms that bought shares according to their most recent 13F filings are: Flagship Ventures Management, Blackrock Institutional Trust, VANGUARD GROUP, MILLENNIUM MANAGEMENT, Bank of New York Mellon, Dynamic Technology, SUSQUEHANNA INTERNATIONAL, KCG Holdings, PRICE T ROWE, and many more.
Revenue YOY is up an incredible 42,661.19%.
Eleven Biotherapeutics Stock Chart
Eleven Biotherapeutics, Inc. is a late clinical-stage company advancing a broad pipeline of anti-cancer agents based on Targeted Protein Therapeutics (TPTs) platform. Our TPTs genetically combine targeting antibody fragments with cytoxic protein payloads to create a single fusion protein through Eleven’s proprietary one-step manufacturing process.